About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Advertisement

Molecules for Promise as New Prostate Cancer Drugs Screened

by Colleen Fleiss on May 12, 2018 at 11:15 PM
Molecules for Promise as New Prostate Cancer Drugs Screened

New research team from the Departments of Pharmacy & Pharmacology and Chemistry studied a protein called α-methylacyl-CoA racemase (AMACR) as a potential target for cancer treatments.

Levels of AMACR protein and activity are increased by ~10-fold in all prostate cancers. Reducing these levels using genetic techniques makes the cancer cells less aggressive, and their behaviour becomes more like normal cells. Until relatively recently finding molecules that could target and inhibit AMACR has been challenging because it's been difficult to accurately measure activity levels of the protein. However, after designing a simple colour-change test which can do precisely that, the University of Bath team were able to start analysing how the structure of promising molecules affects the activity of AMACR.

Advertisement


The team systematically varied the design of drug molecules in order to identify which parts of the molecule are important for effectiveness against AMACR. In particular they confirmed that the 'oiliness' of a molecule is directly related to its potency - oily regions of the drug molecule, which exclude water, can stick to their targets more easily - although this had been predicted, the University of Bath experiments confirm it for the first time. The information from the tests will help the team move towards more promising anti-cancer drugs. Their next steps will be to use the information to design rationally even more potent molecules for testing against AMACR.

The research is published in the journal Bioorganic Chemistry. Lead author Dr Matthew Lloyd said: "This is a small but important step in the development of new treatments for prostate cancer based on AMACR inhibition. It's important because it provides a framework with which to predict and measure drug effectiveness. This will facilitate the development of new treatments for prostate cancer and other cancers in which AMACR levels are increased. "The test that we've developed at Bath makes this sort of work possible and will now allow us to continue to work towards new anti-cancer drugs." The study was funded by Prostate Cancer UK with support from the Movember Foundation as part of their initiative to develop new treatments for prostate cancer.
Advertisement

Dr Matthew Hobbs, Deputy Director of Research at Prostate Cancer UK, said: "Over 11,000 men die from prostate cancer every year in the UK, making it the third biggest cancer killer. In these men prostate cancer cells grow and evolve and eventually become resistant to the treatments currently available to combat the disease. However, important research like this which seeks to find new, innovative ways to treat prostate cancer has the potential to stop this trend. "It's thanks to the funds raised by supporters of Prostate Cancer UK and the Movember Foundation that this research is possible." In the United Kingdom, prostate cancer is the most common male-specific cancer with 47,151 new diagnoses reported in 2015 and 11,287 deaths in 2014. It accounts for 26% of all cancers diagnosed in men, with one in eight men being diagnosed with prostate cancer in their lifetime. Although 84% of men will survive for at least 10 years with the disease, new treatments are urgently needed especially for those men diagnosed with more advanced disease. The paper "Structure-activity relationships of rationally designed AMACR 1A inhibitors" is available online.

Source: Eurekalert
Font : A-A+

Advertisement

Advertisement
Advertisement

Recommended Readings

Latest Cancer News

Personalized Vaccine and T Cell Therapy for Ovarian Cancer Patients
The combination of the personalized cancer vaccine with ACT led to ovarian cancer control in few patients within a span of three months, stated study results.
Kinase-Targeted Therapy Revolutionizes Colorectal Cancer Care
Uncovering key kinases in tumor growth and invasion is crucial for improving targeted therapies in advanced-stage colorectal cancer.
Novel Photo-Oxidation Therapy Holds Promise for Anticancer Treatment
The study findings validate metal-enhanced photo-oxidation for future metal-based anticancer drugs.
Mutations in 11 Genes Linked to Aggressive Prostate Cancer
Mutations in 11 genes are linked to aggressive forms of prostate cancer, which may present novel therapeutic and therapy options.
Link Between Poor Oral Health and Head & Neck Cancer Survival Uncovered
Improved oral health, as indicated by the count of natural teeth and dental appointments preceding the diagnosis, correlated with enhanced head and neck cancer survival rates.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close
MediBotMediBot
Greetings! How can I assist you?MediBot
×

Molecules for Promise as New Prostate Cancer Drugs Screened Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests